A botulinum toxin A treatment algorithm for de novo management of torticollis and laterocollis

Harald Hefter, ¹ Andreas Kupsch, ² Martina Müngersdorf, ³ Sebastian Paus, ⁴ Andrea Stenner, ⁵ Wolfgang Jost, ⁶ on behalf of the Dysport Cervical Dystonia Study Group

ABSTRACT

Objectives: Few studies have investigated the injection patterns for botulinum toxin type A for the treatment of heterogeneous forms of cervical dystonia (CD). This large, prospective, open-label, multicentre study aimed to evaluate the effectiveness and safety of 500 U botulinum toxin A for the initial treatment according to a standardised algorithm of the two most frequent forms of CD, predominantly torticollis and laterocollis.

Design: Patients (aged ≥18 years) with CD not previously treated with botulinum neurotoxin therapy were given one treatment with 500 U Dysport, according to a defined intramuscular injection algorithm based on clinical assessment of direction of head deviation, occurrence of shoulder elevation, occurrence of tremor (all evaluated using the Tsui rating scale) and hypertrophy of the sternocleidomastoid muscle.

Results: In this study, 516 patients were enrolled, the majority of whom (95.0%) completed treatment. Most patients had torticollis (78.1%). At week 4, mean Tsui scores had significantly decreased by −4.01, −3.76 and −4.09 points in the total, torticollis and laterocollis populations, respectively. Symptom improvement was equally effective between groups. Tsui scores remained significantly below baseline at week 12 in both groups. Treatment was well tolerated; the most frequent adverse events were muscular weakness (13.8%), dysphagia (9.9%) and neck pain (6.6%).

Conclusions: Dysport 500 U is effective and well tolerated for the de novo management of a range of heterogeneous forms of CD, when using a standardised regimen that allows tailored dosing based on individual symptom assessment.

Clinical trials information: (NCT00447772; clinicaltrials.gov)

INTRODUCTION

Idiopathic cervical dystonia (CD) is the most frequent form of focal dystonia and is characterised by sustained involuntary muscle contraction and/or twitching of cervical musculature, resulting in head and neck movements as well as various undesired head positions.¹ Depending on the direction of head movement, CD can be commonly classified as torticollis (turning of the head), laterocollis (head and neck tilt), retrocollis (head and neck extension), anterocollis (head and neck flexion) or a combination of the above. A more detailed analysis of the muscles that are involved in CD has recently been performed, taking into account whether the head or the neck is predominantly forced into abnormal positions,² and this analysis may lead to new classification and terminology. However, this has yet to be widely adopted, and the former classification is still routinely used in clinical practice.

Botulinum neurotoxin (BoNT) has a long-standing and widespread use for the treatment of CD and is recommended as the first-line treatment option.³ The efficacy of
Botulinum toxin A (Dysport) for the treatment of CD has been demonstrated in multiple randomised, placebo-controlled trials. These studies have shown that Dysport 500 U is an effective and well-tolerated starting dose for the treatment of CD and provides symptom relief for up to 3 months. Apart from one study specifically investigating the effects of Dysport on torticollis, the other studies have included a heterogeneous CD patient population with the number of injection sites and Dysport dose at each site determined based on investigator judgement. Careful selection of the dose of toxin used per muscle is essential, as inappropriate dosing can increase the risk of adverse events such as focal muscle weakness. Therefore, an injection protocol was predefined in this study, specifying dose and injection sites to minimise the risk of side-effects and systematically evaluate the effectiveness and safety of this dosing algorithm tailored to the individual heterogeneous subtypes of CD. This decision cascade resulted in a corresponding injection protocol defining the dose and number of injection points per muscle (figure 1). This algorithm may help inexperienced users to inject Dysport effectively and safely.

**METHODS**

**Study design and patients**

This was a prospective, multicentre, open-label study conducted in Germany and Austria to investigate the effectiveness and safety of 500 U Dysport for the treatment of heterogeneous forms of CD. As botulinum toxin type A (BoNT-A) is regarded as a first-line neurological therapy for the treatment of CD, this study did not include a placebo-control arm. The study was conducted in accordance with the Declaration of Helsinki, taking into account local regulatory requirements; all patients provided written informed consent to participate.

All patients received 500 U Dysport (Ipsen Biopharm, Wrexham, UK), diluted in 2.5 ml 0.9% NaCl. Treatment was administered by intramuscular injections according to three predefined main decision steps. The investigator had to follow these steps and select (out of the 12 given injection protocols) the best suitable for the individual patient (figure 1):

1. main type of CD (either torticollis or laterocollis based on the Tsui score);
2. shoulder elevation (<2 Tsui score, subscore C) or tremor (tremor, myoclonia, corresponding to Tsui score 4, subscore D), which had to be treated as a second component;
3. presence of hypertrophy of the sternocleidomastoid muscle (marked vs light or no hypertrophy).

This decision cascade resulted in a corresponding injection protocol defining the dose and number of injection points per muscle (figure 1). The injection protocol for shoulder elevation was used when the patient had a shoulder elevation >2 in Tsui subscore C. The injection protocol for tremor was used when the...
patients had a tremor score of 4 in Tsui subscore D. If the patient fulfilled both these criteria, it was the investigator’s decision to treat the symptoms which were the most disabling for the patient and to use the corresponding injection protocol. Electromyography (EMG) guidance for injection was left to the discretion of the investigator.

Assessments
The decision rules follow a careful assessment of severity of CD symptoms using the Tsui scale under standardised conditions with the patient in a relaxed seated position. Assessment of CD symptom severity using the Tsui total score was repeated at weeks 4 and 12 post-treatment. The primary efficacy outcome was a change from baseline to week 4 in Tsui total score after treatment.

In addition, both investigators and patients provided a global assessment efficacy at weeks 4 and 12 post-treatment. This was rated on a four-point scale (1=very good; 2=good; 3=moderate; 4=insufficient).

Safety assessments included incidence of AEs, neurological and physical examinations, vital signs and patient and investigator global assessment of tolerability, rated on a four-point scale (1=very good; 2=good; 3=moderate; 4=insufficient).

Statistical analyses
An original sample size of 600 subjects, enrolled over 24 months, was planned in order to detect a one-point between-treatment group difference on change from baseline to week 4 in Tsui total score with 90% power. However, this target was not reached, and as such, recruitment was stopped at 516 patients after 39 months. Following a data review, the primary statistical analysis plan was regarded as exploratory, and thus no adjustments for multiplicity were made. The safety population included all patients who received study medication and had at least one safety assessment. Effectiveness analyses were conducted on the intention-to-treat population, which included all patients in the safety sample who had at least one baseline and one post-treatment Tsui total score assessment. Additionally, confirmatory analyses using the per-protocol population (excluding major protocol violations) were conducted.

The primary effectiveness endpoint, the mean change in Tsui total score between baseline and week 4, was assessed by analysis of covariance (ANCOVA), with baseline Tsui total score as covariate and the main type of CD as between-group factor. Analyses were conducted for the total population and by main type of CD. The time course of the Tsui total score improvement was investigated by means of repeated-measures ANCOVA models, which included the main type of CD and week of assessment as the main effects and type of CD and week of assessment as covariates. The mean percentage improvement in Tsui total scores at weeks 4 and 12 was also evaluated for each main type of CD; this analysis was specified post-hoc in order to facilitate comparison of the results with other studies. Safety data were analysed descriptively.

RESULTS
Patient disposition and demographics
A total of 516 patients were enrolled in this study at 81 study sites in Germany and Austria. The safety sample consisted of 515 patients; one patient received treatment but was excluded from the safety analysis, as no safety data were available. Patient disposition is shown in figure 2. Four hundred and eighty-nine patients (95.0%) included in the safety sample completed the study.

Patient demographics and baseline characteristics are shown in table 1. The majority of patients had torticollis (n=402; 78.1%); 112 patients (21.7%) had laterocollis; the type of CD was unknown in one patient. Baseline characteristics were similar between patients with torticollis and laterocollis, although the proportion of males was higher in patients with torticollis (32.6%) compared with patients with laterocollis (27.7%). More than half of patients (56.5%) experienced pain associated with CD, and 12.6% of patients had a documented additional sagittal or lateral shift. Twelve patients (2.3%) reported dysphagia before treatment due to head deviation (torticollis n=7 and laterocollis n=5).

Treatments and dosing
All treated patients received Dysport 500 U at baseline with the exception of three patients who received less than 500 U (non-compliance to the injection protocol). All injections were given without EMG guidance. The most frequently reported concomitant medications (>10% of patients) by therapeutic class were beta-blocking agents (19.0%), agents acting on the renin–angiotensin system (14.4%), psychoanaleptics (13.6%), thyroid therapy (13.0%) and analgesics (10.1%). Concomitant medication use was similar between CD types.

Figure 2 Patient disposition. *One patient was excluded from the safety analysis as treatment was discontinued prematurely due to insufficient compliance. No safety data was collected for this patient.
Dysport for the treatment of cervical dystonia

Table 1  Baseline patient demographics: safety sample

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Torticollis (n=402)</th>
<th>Laterocollis (n=112)</th>
<th>Total* (n=515)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender, n (%) male</td>
<td>131 (32.6)</td>
<td>31 (27.7)</td>
<td>162 (31.5)</td>
</tr>
<tr>
<td>Age, years</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean (SD)</td>
<td>51.9 (12.7)</td>
<td>51.9 (12.8)</td>
<td>51.9 (12.7)</td>
</tr>
<tr>
<td>Range</td>
<td>19–83</td>
<td>19–87</td>
<td>19–87</td>
</tr>
<tr>
<td>Height, cm (mean (SD))†</td>
<td>169.1 (8.6)</td>
<td>168.4 (8.7)</td>
<td>169.0 (8.6)</td>
</tr>
<tr>
<td>Weight, kg (mean (SD))†</td>
<td>73.2 (15.4)</td>
<td>70.7 (12.1)</td>
<td>72.6 (14.7)</td>
</tr>
<tr>
<td>BMI, kg/m² (mean (SD))†</td>
<td>25.5 (4.6)</td>
<td>24.9 (3.6)</td>
<td>25.3 (4.4)</td>
</tr>
<tr>
<td>Race, n (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Caucasian</td>
<td>398 (99.0)</td>
<td>112 (100.0)</td>
<td>511 (99.2)</td>
</tr>
<tr>
<td>Asian</td>
<td>1 (0.2)</td>
<td>0 (0.0)</td>
<td>1 (0.2)</td>
</tr>
<tr>
<td>Oriental</td>
<td>3 (0.7)</td>
<td>0 (0.0)</td>
<td>3 (0.6)</td>
</tr>
<tr>
<td>Additional CD symptoms, n (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pain (p=0.0676‡)</td>
<td>219 (54.5)</td>
<td>72 (64.3)</td>
<td>291 (56.5)</td>
</tr>
<tr>
<td>Shift (sagittal or lateral, p=0.0011‡)</td>
<td>40 (10.0)</td>
<td>25 (22.3)</td>
<td>65 (12.6)</td>
</tr>
<tr>
<td>Dysphagia (p=0.1467‡)</td>
<td>7 (1.7)</td>
<td>5 (4.5)</td>
<td>12 (2.3)</td>
</tr>
<tr>
<td>Other</td>
<td>12 (3.0)</td>
<td>1 (0.9)</td>
<td>13 (2.5)</td>
</tr>
<tr>
<td>Subtypes of CD, n (%)§</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Without tremor/shoulder elevation (p=0.0006‡)</td>
<td>131 (32.6)</td>
<td>18 (16.1)</td>
<td>149 (29.0)</td>
</tr>
<tr>
<td>With shoulder elevation (p=0.0024‡)</td>
<td>126 (31.3)</td>
<td>53 (47.3)</td>
<td>179 (34.8)</td>
</tr>
<tr>
<td>With tremor (p=0.9120‡)</td>
<td>145 (36.1)</td>
<td>41 (36.6)</td>
<td>186 (36.2)</td>
</tr>
<tr>
<td>Baseline total Tsui score (patient in sitting position), mean (SD)§</td>
<td>8.4 (3.5)</td>
<td>8.2 (3.3)</td>
<td>8.4 (3.5)</td>
</tr>
</tbody>
</table>

*Includes one patient in whom the main type of cervical dystonia (CD) was unknown.
†Torticollis n=399; laterocollis n=111; total n=510.
‡Fisher exact test for torticollis versus laterocollis, two-sided.
§Total population n=514, main type of CD was not known in one patient.

Efficacy

For the primary efficacy endpoint, Dysport significantly decreased mean Tsui total scores from baseline to week 4 (−3.83; 95% CIs −4.01 to −3.57; p<0.0001) in the total population. Dysport also significantly decreased Tsui total scores from baseline to week 4 for patients with torticollis (−3.76; 95% CI −4.02 to −3.51; p<0.0001) and patients with laterocollis (−4.09; 95% CI −4.58 to −3.59; p<0.0001), corresponding to a percentage improvement of 43.7±36.4% and 46.5±28.3%, respectively (total population: 44.3±34.8%). The mean treatment difference between the torticollis and laterocollis groups was not statistically significant (−0.32; 95% CI −0.88 to 0.23; p=0.255), indicating that both forms of CD equally improved at week 4.

Significant improvements in Tsui total scores were sustained to week 12 for both CD types (figure 3), corresponding to similar percentage improvements in patients with torticollis (23.6±44.6%) and laterocollis (27.0±33.0%) (total population 24.3±42.4%).

Analysis of data using the per-protocol population (n=490) confirmed findings from the intention-to-treat analysis (n=503).

In analyses of the total population, the mean changes in Tsui subscale scores from baseline to week 4 were statistically significant for all Tsui subscores: amplitude of rotation, deflection (tilt) and anter-/postero-collis, subscore A: −1.4; 95% CI −1.5 to −1.3; duration of movement, subscore B: −0.3; 95% CI −0.4 to −0.3; severity and duration of shoulder elevation, subscore C: −0.4; 95% CI −0.5 to −0.3; and tremor, subscore D: −0.6; 95% CI −0.7 to −0.5. The percentage improvement between the mean Tsui score at baseline and V2 was greatest for severity of tremor (45%, subscore D) and least for duration of movement (22%, subscore B). The percentage improvement in mean values between baseline and V2 was 40% each for subscores A (amplitude) and C (shoulder elevation), respectively.

Figure 3  Mean Tsui total scores at baseline, week 4 and week 12 in the main CD subtypes and the total population (ITT population). *p<0.0001 vs baseline. The reduction of the Tsui total score was highly significant both at week 4 and 12 (p<0.0001) and, as is evident from the parallel lines, nearly identical in the torticollis and laterocollis patient groups. CD, cervical dystonia; ITT, intention-to-treat.
The efficacy of study medication in the total population was rated as ‘very good’ or ‘good’ by 70.0% of investigators (67.2% torticollis, 80.2% laterocollis) and 60.8% of patients (59.9% torticollis, 64.1% laterocollis) at week 4. At week 12, efficacy was rated as ‘very good’ or ‘good’ by 72.0% of investigators (70.4% torticollis, 77.9% laterocollis) and 64.9% of patients (63.8% torticollis, 69.3% laterocollis).

Safety and tolerability
At least one AE was experienced by 41.4% of patients, of which 30.1% were considered to be related to study medication. The most frequent AEs (>5% of patients) were muscular weakness (13.8%), dysphagia (9.9%) and neck pain (6.6%); no significant difference in the rates of these AEs was seen between patients with torticollis and laterocollis, except for severe muscular weakness (table 2). Most AEs were mild to moderate in severity (89.7%); only 53 patients (10.3%) experienced severe AEs. A summary of safety and tolerability by main type of CD is shown in table 2. Overall, AEs of muscular weakness, dysphagia and neck pain were rated as severe in 17 (3.3%), three (0.6%) and 13 (2.5%) patients, respectively (table 2). One patient experienced severe dysphagia, severe muscular weakness and severe neck pain simultaneously, and five patients experienced both severe muscular weakness and severe neck pain. Nearly all cases of severe muscular weakness (15 of 17 patients; 88.2%) and all cases of severe dysphagia (three patients) resolved without the requirement for intervention. Of the two patients with severe muscle weakness that were not classed as resolved, no information was available for one patient, and one patient had to wear a cervical collar temporarily. Of the patients with severe neck pain (n=13), six (46.2%) had pain that was self-limiting and did not require intervention, while the other seven (53.8%) required intervention.

Eleven patients (2.1%) experienced serious AEs (SAEs), although only two patients experienced serious AEs that were considered possibly related to study medication. One patient with torticollis experienced a convulsive syncope together with bradycardia immediately after injection; these symptoms resolved without intervention after several hours, and an EEG revealed no pathological findings. The attending physician assessed the events as probably being an injection-related, vagal reaction. One patient with laterocollis experienced muscle weakness of the head and depression: these symptoms developed 2 days post-treatment, and the patient was hospitalised 11 days post-treatment and treated with antidepressant medication. The patient recovered from both events within 3 weeks.

There were no relevant or unexpected observations in the physical and neurological examination or changes in vital signs with Dysport treatment. Tolerability of study medication, as assessed by investigators and patients, is summarised in table 2.

**DISCUSSION**

This study is the largest prospectively designed study conducted to date in de novo patients with CD, as well as one of the largest studies conducted in patients with CD in general. The results of this study, conducted at multiple centres in Germany and Austria, demonstrate that a single dose of Dysport 500 U can be used effectively for the management of the most common forms of CD.
CD (predominantly torticollis and laterocollis), when being injected according to a standardised algorithm that allows tailored dosing based on individual symptom assessment. Dysport treatment resulted in a clinically and statistically significant improvement in symptoms of CD at week 4, as assessed by Tsui total scores, and the magnitude of improvement was comparable between torticollis and laterocollis patients. Furthermore, in both groups, the benefit of Dysport treatment was maintained to week 12.

The present results agree with previous studies that demonstrated the effectiveness of 500 U Dysport for the treatment of CD and expand on these findings to demonstrate the comparable effectiveness of Dysport in the two main subtypes of CD. Dysport treatment in this study resulted in a greater than 40% improvement in CD symptoms at week 4 in all CD types, as measured by improvement in Tsui scores. This compares well with the percentage improvement in Tsui scores at week 4 in patients treated with Dysport in a double-blind placebo controlled study (Dysport 41% vs placebo 17%; p=0.002).7

Improvements in symptoms were confirmed by investigator and patient global assessment of symptoms without distinct (significant) group differences. Of note, investigator and patient ratings varied most in the laterocollis group at week 4, which could probably be explained by the higher rate of severe muscular weakness reported in these patients.

The treatment protocol used in this study represents a clinically useful treatment algorithm to individualise treatment in approximately 90% of all CD subgroups, that is, torticollis and laterocollis, both with and without shoulder elevation or tremor, also accounting for hypertrophy of the sternocleidomastoid muscle. Independently, it is still essential for treating physicians to understand the biomechanical effects of the muscles involved in the primary movements of the head in order to optimise treatment when using this algorithm. The majority of patients with CD may be treated by the present investigated, standardised injection protocol. However, this protocol may not be suitable for patients with rare, more complex forms of CD. Thus, injection algorithms may facilitate effective dosing of BoNT-A, as excess dosing into muscles not involved in CD symptoms may not improve efficacy but rather increase the risk of AEs. The findings of this study support the use of one vial of 500 U Dysport as an appropriate starting dose for patients with CD and comply with findings of a recent long-term follow-up of Dysport in CD, suggesting that the majority of patients can benefit from this dose over the longer term, given a careful injection technique.10

The algorithm presented allows the optimal distribution of one 500 U vial of Dysport based on the patient’s clinical picture, assessed by the Tsui score, and is practicable in a normal clinical setting.

Dysport was well tolerated for the treatment of CD in this study; most AEs were mild to moderate in severity, and the majority of patients and investigators rated treatment tolerability as very good/good, regardless of torticollis or laterocollis. Interestingly, and as seen in the efficacy ratings, investigator and patient ratings of tolerability varied most in the laterocollis group at week 4. It is possible that the statistically significant difference in severe muscular weakness between torticollis and laterocollis patients explains why laterocollis patients rated their tolerability of study treatment lower than torticollis patients at week 4. No new safety concerns were raised by this study, and the most common AEs reported, muscular weakness and dysphagia, were consistent with the known safety profile of this medication in this indication.11

The reported rates of muscle weakness and dysphagia were consistent with those reported for Botox in de novo patients, although there are inherent limitations in comparing data, assessment methods and botulinum toxin A formulations between studies. Rates of dysphagia and muscular weakness presented here are lower than rates reported in previously conducted double-blind, placebo-controlled trials with Dysport, probably due to dose distribution of Dysport based on a predefined injection protocol. Specifically, with regard to dysphagia, the majority of the BoNT-A dose in this study was injected into the posterior part of the neck region. Thus, the results show that the use of predefined injection protocols allowing individual symptom treatment may have the potential to improve treatment tolerability by providing patients with effective symptom relief while possibly limiting AEs associated with injecting non-involved muscles. Finally, it is important to point out that the injection protocol may guide the initial treatment in de novo patients with CD. However, the dose and muscle selection of further injections should always consider the patient’s individual symptoms in conjunction with the initial treatment outcomes. Careful and extensive clinical examination and diagnosis are essential in all patients, especially those presenting with symptoms of pain and dysphagia caused by head deviation.

In conclusion, Dysport 500 U is effective and well tolerated for the de novo treatment of the majority of patients suffering from the most common forms of CD. Analyses of additional secondary effectiveness outcomes collected in this study will provide further insight into the benefits of Dysport in this de novo patient group.

Author affiliations
1Department of Neurology, University of Düsseldorf, Moorenstrasse, Düsseldorf, Germany
2Department of Neurology, University Hospital Charité, Campus Virchow-Klinikum, Augustenburger Platz, Berlin, Germany
3Neurologie am Hackeschen Markt, Dircksenstr, Berlin, Germany
4Department of Neurology, University of Bonn, Sigmund-Freud-Strasse, Bonn, Germany
5Out-Patient Department of Neurology, Paracelsus Klinik, Werdauer Strasse, Zwickau, Germany
6Department of Neurology, Deutsche Klinik für Diagnostik Wiesbaden, Aukammallee, Wiesbaden, Germany
Acknowledgements Data management and statistical analyses were performed by GKM Gesellschaft für Therapieforschung in Munich, Germany. Editorial assistance for the preparation of this manuscript was provided by Ogilvy Healthworld Medical Education. The authors would like to thank C Colling, Medical Project Manager, Ipsen Pharma GmbH, for her assistance in the conduct of the study and for reviewing the manuscript.

Correction notice The “To cite: …” information and running footer in this article have been updated with the correct volume number (volume 1).

Funding Funding was provided by Ipsen Pharma, Germany.

Competing interests HH: consultant and speaker for Ipsen; AK: speaker honoraria from Ipsen; MM: speaker for Ipsen; SP: consultant and speaker for Ipsen; AS: speaker for Ipsen; WJ: consultant and speaker for Ipsen.

Patient consent Obtained.

Ethics approval Ethics approval was provided by Ethics Committee of the Medical Faculty of the Heinrich-Heine University of Düsseldorf, Moorenstrasse, Düsseldorf, Germany (Lead EC) and local Ethics Committees.

Contributors HH and WJ were involved in the concept and study design, study conduct, data collection, analysis and interpretation, manuscript writing, review and critique. All other authors were involved in conducting the study, data collection, manuscript review and critique. All authors approved the final manuscript.

Provenance and peer review Not commissioned; externally peer reviewed.

Data sharing statement Data management and statistical analyses were performed by GKM Gesellschaft für Therapieforschung in Munich, Germany.

REFERENCES


APPENDIX 1

Dysport Cervical Dystonia Study Group

Members of the Dysport Cervical Dystonia Study Group in Germany were (in alphabetical order of study sites): H Eing (Ahaua); A Pleeu (Apolda); B Patzner (Arnsdorf); H Griese (Bad Oeynhausen); M Pott (Bayreuth); A Nebe, T Winter and J Wissel (Beiltz-Heilstätten); H Woldag (Bennewitz); W Raffauf (Berlin); K Till-Wilck (Berlin); AM Garcia, D Gruber, F Kempf, H Krug, E Lobbsien (Berlin); Leisten (Berlin); A Schenkkel-Römer (Berlin); S Eue (Bernburg); M Borsei (Bielefeld); I Nastos (Bochum); S Otto (Bochum); T Greli and M Tengtoff (Bochum); E Mkke (Bremen); E Kunesch, T Probst and M Richter (Deggenroed); A Hermann and M Wolz (Dresden); M Kahlen and M Moll (Düsseldorf); A Grüsser (Eberswalde); P Feise, H W Kölmel and L Kotthaus (Erfurt); M Haslecki (Erfangen); A Jaspert-Grell (Essen); M Maschke, M Obermann and N Putzki (Essen); J Böhm (Freiberg); C Schiel (Gießen); M Hahn (Gießen); I Reuter and S Schmidt (Gießen); H Krumpolt (Grossschweidnitz); FM Brake (Hagen); F Hoffmann and C Wohlrab (Halle-Dölaü); V Becker and T Humber (Hamburg); B Mohammedi (Hannover); R Dengler, K Kollewe, K Krampfli and S Petri (Hannover); G Osterhage (Homburg); D Müller (Ilmenau); K Gehring (Itzehoe); G Heide and A Jentsch (Jena); M Margenthaler (Kaiserslautern); J Volkman (Kiel); U Marczyński and J Wöhrle (Koblenz); R Wittke (Landshut); S Peschel (Leipzig); P Baum (Leipzig); R Schneider (Lemgo); J Hagenah (Lübeck); K-A Bohr (Lüneburg); H Bätzner and C Blahak (Mannheim); J Philips (Minden); R Althoff, J Haan and K Kessler (Mönchen-gladbach); F Castrop, C Dresel, L Esposito, C Loer and B Haslinger (München); AO Ceballos-Baumann, U Fietzek, M Messner and L Riedl (München); M Ritter and P Young (Münster); F Ergbuth (Nürnberg); R Witte (Oldenburg); M Putzer (Paderborn); J Kursawe (Potsdam); R Witke (Potsdam); K Stutterheim (Potsdam); J Vollmer-Haase (Recklinghausen); R Benecke (Rostock); M Schönfeld (Rudersdorf); E Fleischer (Schöm-dorf); A Negro (Schwedt/Öder); A Bartels (Schwerin); T Warnecke (Seesen); R Roick (Singen); M Petrick (Teupitz); J Hahn (Weiden); A Nebe, T Winter and J Wissel (Beelitz-Heilstätten); M Ritter and P Young (Münster); F Erbguth (Nürnberg); R Witte (Oldenburg); F Leise (Oberläub); C Blahak and H Krumpolt (Grossschweidnitz); F Brake (Ilmenau); K Gehring (Itzehoe); G Heide and A Jentsch (Jena); F Castrop, C Dresel, L Esposito, C Loer and B Haslinger (München); AO Ceballos-Baumann, U Fietzek, M Messner and L Riedl (München); M Ritter and P Young (Münster); F Ergbuth (Nürnberg); R Witte (Oldenburg); M Putzer (Paderborn); J Kursawe (Potsdam); K Stutterheim (Potsdam); J Vollmer-Haase (Recklinghausen); R Benecke (Rostock); M Schönfeld (Rudersdorf); E Fleischer (Schöm-dorf); A Negro (Schwedt/Öder); A Bartels (Schwerin); T Warnecke (Seesen); R Roick (Singen); M Petrick (Teupitz); J Hahn (Weiden); E Fucik, S Heimann and B Zeiler (Wiesbaden); P Cordes and J Schierenbeck (Wolfenbüttel); C Helbig, M Klein and K-U Oehler (Würzburg); M Beck and A Schramm (Würzburg); G Hennem (Wuppertal); G Reichel (Zwickau).

Members of the Dysport Cervical Dystonia Study Group in Austria were (in alphabetical order of study sites): D J Diez (Graz); P Schnieder (Grimmstein-Hochegg); T Haydn, J Müller and W Poewe (Innsbruck); RJ Resch and R Sommer (Linz).
### STROBE statement: Checklist of essential items Version 3 (Sept 2005)

<table>
<thead>
<tr>
<th></th>
<th>Item #</th>
<th>Cohort study</th>
<th>Case-control study</th>
<th>Cross-sectional study</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>TITLE &amp; ABSTRACT</strong></td>
<td>1</td>
<td>(a) Identify the article as a cohort study in the title or the abstract.</td>
<td>(a) Identify the article as a case-control study in the title or the abstract.</td>
<td>(a) Identify the article as a cross-sectional study in the title or the abstract.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>(b) The abstract should be an informative and structured summary of the article, addressing key items in this checklist.</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>INTRODUCTION</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Background / Rationale</td>
<td>2</td>
<td>Explain scientific background and rationale for the investigation being reported.</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>OBJECTIVES</strong></td>
<td>3</td>
<td>State specific objectives including any pre-specified hypotheses.</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>METHODS</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Study design</td>
<td>4</td>
<td>Present key elements of study design. State purpose of original study, if article is one of several from an ongoing study.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Setting</td>
<td>5</td>
<td>Describe setting, locations and dates defining periods of data collection.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Participants</td>
<td>6</td>
<td>(a) Give inclusion and exclusion criteria, sources and methods of selection of participants.</td>
<td>(a) For cases and controls separately, give inclusion and exclusion criteria, sources and methods of selection.</td>
<td>(a) Give inclusion and exclusion criteria, sources and methods of selection of participants.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>(b) Give period and methods of follow-up.</td>
<td>(b) Give precise diagnostic criteria for cases, and rationale for choice of controls.</td>
<td></td>
</tr>
<tr>
<td>Item #</td>
<td>Cohort study</td>
<td>Case-control study</td>
<td>Cross-sectional study</td>
<td></td>
</tr>
<tr>
<td>--------</td>
<td>-------------</td>
<td>--------------------</td>
<td>-----------------------</td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>Variables of interest</td>
<td>List and clearly define all variables of interest indicating which are seen as outcomes, exposures, potential predictors, potential confounders or effect modifiers.</td>
<td>(c) For matched studies, give matching criteria and number of controls per case.</td>
<td></td>
</tr>
<tr>
<td>8 *</td>
<td>Measurement</td>
<td>(a) For each variable of interest give details of methods of assessment (measurement). (b) If applicable, describe comparability of assessment methods across groups.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>9</td>
<td>Bias</td>
<td>Describe any measures taken to address potential sources of bias.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>Sample size</td>
<td>Describe rationale for study size, including practical and statistical considerations.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11</td>
<td>Statistical methods</td>
<td>(a) Describe all statistical methods including those to control for confounding. (b) Describe how any matching of cases and controls and missing data were addressed. (b) Describe how any design effects and missing data were addressed. (c) If applicable, describe methods for subgroup analyses and sensitivity analyses.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12</td>
<td>Quantitative variables</td>
<td>(a) Explain how quantitative variables are analyzed e.g. which groupings are chosen, and why. (b) Present results from continuous analyses as well as from grouped analyses, if appropriate.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* Give such information separately for cases and controls in case-control studies, and if applicable for exposed and unexposed groups in cohort and cross-sectional studies.
Give such information separately for cases and controls in case-control studies, and if applicable for exposed and unexposed groups in cohort and cross-sectional studies.

<table>
<thead>
<tr>
<th>Item #</th>
<th>Cohort study</th>
<th>Case-control study</th>
<th>Cross-sectional study</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Funding</strong></td>
<td>13</td>
<td>Give source of funding and role of funder(s) for the present study and, if applicable, the original study on which the present article is based.</td>
<td></td>
</tr>
</tbody>
</table>

**RESULTS**

**Participants** 14 *

(a) Report the numbers of individuals at each stage of the study, e.g. numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow up, and analysed.

(b) Give reasons for non-participation at each stage.

(c) A flow diagram is recommended.

(d) Report dates defining period of recruitment.

(e) For matched studies, give distribution of number of controls per case.

**Descriptive data** 15 *

(a) Give characteristics of study participants (e.g. demographic, clinical, social) and information on exposures and potential confounders

(b) Indicate for each variable of interest the completeness of the data.

(c) Summarize average and total amount of follow up and dates defining follow up.

**Outcome data** 16 *

Report numbers of outcome events or summary measures over time.

Report numbers in each exposure category.

Report numbers of outcome events or summary measures.

* Give such information separately for cases and controls in case-control studies, and if applicable for exposed and unexposed groups in cohort and cross-sectional studies.
Give such information separately for cases and controls in case-control studies, and if applicable for exposed and unexposed groups in cohort and cross-sectional studies.

<table>
<thead>
<tr>
<th>Item #</th>
<th>Cohort study</th>
<th>Case-control study</th>
<th>Cross-sectional study</th>
</tr>
</thead>
</table>
| **Main results** | 17 | (a) Give unadjusted and confounder adjusted measures of association and their precision (e.g. 95% confidence intervals). Make clear which confounders were adjusted for and on what grounds they were included and others were not.  
(b) For comparisons using categories derived from quantitative variables, report the range of values or median value in each group.  
(c) Translate relative measures into absolute differences, for a meaningful risk period that does not extend beyond the range of the data.  
(d) Report results standardized to confounder and modifier distributions for realistic target populations. | |
| **Other analyses** | 18 | Report any other analyses performed, e.g. subgroup analyses and sensitivity analyses. | |

**DISCUSSION**

| Key findings | 19 | Summarize key results with reference to study hypotheses. | |
| Limitations | 20 | (a) Discuss limitations of the study, taking into account sources of potential bias or imprecision, and problems that could arise from multiplicity of analyses, exposures and outcomes. Discuss both direction and magnitude of any potential bias.  
(b) Consider that the discussion of limitations should not be used as a substitute for quantitative sensitivity analyses. | |
| Generalizability | 21 | Discuss the generalizability (external validity) of the study findings. | |
| Interpretation | 22 | Give a cautious overall interpretation of the results in the context of current evidence and study limitations, paying attention to alternative interpretations. | |